key: cord-1023361-xb0c2u3n authors: Versmissen, Jorie; Verdonk, Koen; Lafeber, Melvin; van den Akker, Johannes P.C.; Hunfeld, Nicole G.M.; Hoorn, Ewout J.; Danser, A.H. Jan title: Angiotensin-converting enzyme-2 in SARS-CoV-2 infection: good or bad? date: 2020-05-06 journal: J Hypertens DOI: 10.1097/hjh.0000000000002472 sha: bb82d38a2d04c7958ff91c1feafcb80ef6047f17 doc_id: 1023361 cord_uid: xb0c2u3n nan neutral [14, 15] . ARBs are suggested to upregulate the pathway involving ACE2 and angiotensin-(1-7) but again data are conflicting, and differ per ARB and per organ [15] [16] [17] . For instance, ARBs may increase ACE2 activity but not its expression, which is most important for binding of virus particles [14] . Importantly, reduced ACE2 expression associates with worse cardiovascular and pulmonary outcomes, for example, in acute respiratory distress syndrome (ARDS) and shock [18, 19] . After the SARS epidemic in 2003, studies were done concerning ACE2. Here it is of interest to note that SARS-CoV binding lowers ACE2 expression, thereby deteriorating ARDS in a mouse model [10] . Diminished myocardial ACE2 expression also facilitates inflammation and damage [20] , and low ACE2 activity predisposes for hypertension and diabetes and their cardiovascular complications [21, 22] . From this perspective, cardiovascular patients with low ACE2 expression would actually be least susceptible to SARS-Cov-2 infection. However, once the infection occurs, lower ACE2 activity as a consequence of virus particle binding would rapidly deteriorate their situation. Simultaneously, RAS blockers, if exerting their effects in these patients via ACE2 upregulation, would be the most desirable drugs [21, 23] . Of course, none of this is clinically proven. At this stage, we urgently need detailed data (blood pressure, drug treatment) on the hypertensive and diabetic patients dying from SARS-Cov-2 infection. Until that time, there is no reason to abandon RAS blockers as recently underlined by societies, such as the European Society of Hypertension (https://www.eshonline.org/spotlights/eshstabtement-on-covid-19/) massively stopping RAS blockers could potentially lead to: uncontrolled blood pressure, worse cardiovascular outcomes, and death. To study the role of ACE2 expression in the clinical course of SARS-CoV-2, future studies should determine ACE2 expression, particularly after virus exposure. If indeed lower ACE2 is confirmed, RAS blockers might be the drugs of first choice. In summary, the current knowledge gaps are whether ACE2 quantity determines the degree of SARS-Cov-2 infection, whether such infection further lowers ACE2, whether low ACE2 quantity in cardiovascular patients truly relates to outcome, and whether the proven beneficial effects of RAS blockers in these patients is related to ACE2 regulation. The current pandemic is a major challenge for global health care. Therefore, unravelling the pathogenic pathways should be the highest priority to enable therapeutic options to improve outcomes. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2 COVID-19 and the cardiovascular system SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic? Angiotensin-converting enzyme II in the heart and the kidney Angiotensin-converting enzyme 2 in lung diseases Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63 A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury Counter-regulatory renin-angiotensin system in cardiovascular disease Novel therapeutic approaches targeting the reninangiotensin system and associated peptides in hypertension and heart failure A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9 Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2 Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors ACE inhibition, ACE2 and angiotensin-(1-7) axis in kidney and cardiac inflammation and fibrosis The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang (1-7)-Mas axes in pressure overload-induced cardiac remodeling in male mice Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock Angiotensinconverting enzyme 2 protects from severe acute lung failure SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS ACE2 gene polymorphism and essential hypertension: an updated meta-analysis involving 11,051 subjects Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor axis Impact of ACE2 deficiency and oxidative stress on cerebrovascular function with aging There are no conflicts of interest.